207_Combined course Presentations

Targeted treatments

• Anti-angiogenesis – Bevacizumab

• Ribonucleotide reductase inhibitor – Triapine

• Tyrosine kinase inhibitors – Sunitinib, sorafenib, imatinib, pazopanib, cediranib

• Immunotherapy

– Adoptive T-cell therapy – ADXS11-001 (axamilogene)

• EGFR inhibitors

– Gefitinib, erlotinib, cetuximab, lapatinib, trastuzumab, panitumumab